Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective
6
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is approved for the treatment of fibromyalgia and several neuropathy. It has been proven to show analgesic, anxiolytic, anticonvulsant and sleep enhancement effects, which could be applicable in the treatment of a variety of psychiatric disorders. There have been consistent reports that unexplained somatic symptoms (i.e., pain) may be a part of psychiatric disorders such as major depressive disorder (MDD) and anxiety disorders. Previous researches have also suggested the possible therapeutic potential of anticonvulsants as augmentation therapy or monotherapy in the treatment of mood disorders and anxiety disorders. Hence this short perspective tries to prompt and facilitate a shifting of researchers’ attention to potential neuropsychotropic drug role of pregabalin to treat a wide range of neuropsychiatric disorders.
Abstract
Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is approved for the treatment of fibromyalgia and several neuropathy. It has been proven to show analgesic, anxiolytic, anticonvulsant and sleep enhancement effects, which could be applicable in the treatment of a variety of psychiatric disorders. There have been consistent reports that unexplained somatic symptoms (i.e., pain) may be a part of psychiatric disorders such as major depressive disorder (MDD) and anxiety disorders. Previous researches have also suggested the possible therapeutic potential of anticonvulsants as augmentation therapy or monotherapy in the treatment of mood disorders and anxiety disorders. Hence this short perspective tries to prompt and facilitate a shifting of researchers’ attention to potential neuropsychotropic drug role of pregabalin to treat a wide range of neuropsychiatric disorders.
참고문헌 (26)
- Rickels K, "Pregabalin for treatment of generalized anxiety disorder:a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam", Arch Gen Psychiatry, 62, pp.1022~1030 (2005)
- Gajraj NM, "Pregabalin: its pharmacology and use in pain management", Anesth Analg, 105, pp.1805~1815 (2007)
- Crofford LJ, "Pregabalin for the treatment of fibromyalgia syndrome:results of a randomized, double-blind, placebo-controlled trial", Arthritis Rheum, 52, pp.1264~1273 (2005)
- Mease PJ, "A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia", J Rheumatol, 35, pp.502~514 (2008)
- Crofford LJ, "Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebocontrolled trial with pregabalin", Pain, 136, pp.419~431 (2008)
- Arnold LM, "A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia", J Pain, 9, pp.792~805 (2008)
- Zohar J, "Brief post-stressor treatment with pregabalin in an animal model for PTSD: shortterm anxiolytic effects without long-term anxiogenic effect", Eur Neuropsychopharmacol, 18, pp.653~666 (2008)
- Hindmarch I, "A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo", Sleep, 28, pp.187~193 (2005)
- Hindmarch I, "A double-blind, placebo- and positiveinternal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers", Psychopharmacology, 183, pp.133~143 (2005)
- Ha KY, "Pregabalin as a neuroprotector after spinal cord injury in rats", Eur Spine J, 17, pp.864~872 (2008)
- André V, "Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat", Epilepsia, 44, pp.893~903 (2003)
- Ratcliffe GE, "Chronic pain conditions and suicidal ideation and suicide attempts: an epidemiologic perspective", Clin J Pain, 24, pp.204~210 (2008)
- Pae CU, "The relationship between fibromyalgia and major depressive disorder: a comprehensive review", Curr Med Res Opin, 24, pp.2359~2371 (2008)
- Lundberg G, "Tender point scores and their relations to signs of mobility, symptoms, and disability in female home care personnel and the prevalence of fibromyalgia syndrome", J Rheumatol, 29, pp.603~613 (2002)
- Pande AC, "Pregabalin in generalized anxiety disorder: a placebo-controlled trial", Am J Psychiatry, 160, pp.533~540 (2003)
- Pande AC, "Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study", J Clin Psychopharmacol, 24, pp.141~149 (2004)
- Feltner DE, "A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder", J Clin Psychopharmacol, 23, pp.240~249 (2003)
- Stein DJ, "Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder:a pooled analysis of 6 studies", Eur Neuropsychopharmacol, 18, pp.422~430 (2008)
- Pohl RB, "Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebocontrolled comparison of BID versus TID dosing", J Clin Psychopharmacol, 25, pp.151~158 (2005)
- Montgomery SA, "Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebocontrolled comparison of pregabalin and venlafaxine", J Clin Psychiatry, 67, pp.771~782 (2006)
- Hidalgo RB, "An effect-size analysis of pharmacologic treatments for generalized anxiety disorder", J Psychopharmacol, 21, pp.864~872 (2007)
- Biermann T, "Pregabalin in benzodiazepine withdrawal", Pharmacopsychiatry, 40, pp.292~293 (2007)
- Oulis P, "Pregabalin in the discontinuation of long-term benzodiazepines’ use", Hum Psychopharmacol, 23, pp.337~340 (2008)
- Stevens JC, "Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents", J Clin Psychiatry, 66(2), pp.21~27 (2005)
- Pae CU, "Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study", Int Clin Psychopharmacol, 24, pp.29~33 (2009)
- Cortese BM, "The role of glutamate in anxiety and related disorders", CNS Spectr, 10, pp.820~830 (2005)